ClearPoint Neuro Q2 revenue $10.9M (+18% YoY); revises 2026 guidance to $48-52M

ClearPoint Neuro, Inc.

Q2 revenue $10.9M (+18% YoY); Biologics & Drug Delivery revenue fell 15% to $4.0M.
Neurosurgery navigation revenue surged 62% to $5.6M on IRRA flow and software.
Operating expenses rose 51% to $17.0M; cash at $29.4M, down from $45.9M at year-end.
2026 revenue guidance revised to $48-52M; company prioritizing clinical capacity and new tech.
Multiple biopharma partners received positive FDA feedback; expects 10-15 trials enrolling in 18 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.